Skip to main navigation Skip to search Skip to main content

Whole-body [18 f]fdg pet/ct can alter diagnosis in patients with suspected rheumatic disease

  • Matthias Fröhlich
  • , Sebastian Serfling
  • , Takahiro Higuchi
  • , Martin G. Pomper
  • , Steven P. Rowe
  • , Marc Schmalzing
  • , Hans Peter Tony
  • , Michael Gernert
  • , Patrick Pascal Strunz
  • , Jan Portegys
  • , Eva Christina Schwaneck
  • , Ottar Gadeholt
  • , Alexander Weich
  • , Andreas K. Buck
  • , Thorsten A. Bley
  • , Konstanze V. Guggenberger
  • , Rudolf A. Werner

Research output: Contribution to journalArticlepeer-review

Abstract

The 2-deoxy-d-[18 F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [18 F]FDG PET/CT on change in initially suspected diagnosis in patients at the time of the scan. Thirty-four patients, who had undergone [18 F]FDG PET/CT, were enrolled and the initially suspected diagnosis prior to [18 F]FDG PET/CT was compared to the final diagnosis. In addition, a semi-quantitative analysis including vessel wall-to-liver (VLR) and joint-to-liver (JLR) ratios was also conducted. Prior to [18 F]FDG PET/CT, 22/34 (64.7%) of patients did not have an established diagnosis, whereas in 7/34 (20.6%), polymyalgia rheumatica (PMR) was suspected, and in 5/34 (14.7%), giant cell arteritis (GCA) was suspected by the referring rheumatologists. After [18 F]FDG PET/CT, the diagnosis was GCA in 19/34 (55.9%), combined GCA and PMR (GCA + PMR) in 9/34 (26.5%) and PMR in the remaining 6/34 (17.6%). As such, [18 F]FDG PET/CT altered suspected diagnosis in 28/34 (82.4%), including in all unclear cases. VLR of patients whose final diagnosis was GCA tended to be significantly higher when compared to VLR in PMR (GCA, 1.01 ± 0.08 (95%CI, 0.95–1.1) vs. PMR, 0.92 ± 0.1 (95%CI, 0.85–0.99), p = 0.07), but not when compared to PMR + GCA (1.04 ± 0.14 (95%CI, 0.95–1.13), p = 1). JLR of individuals finally diagnosed with PMR (0.94 ± 0.16, (95%CI, 0.83–1.06)), however, was significantly increased relative to JLR in GCA (0.58 ± 0.04 (95%CI, 0.55–0.61)) and GCA + PMR (0.64 ± 0.09 (95%CI, 0.57–0.71); p < 0.0001, respec-tively). In individuals with a suspected diagnosis of rheumatic disease, an inflammatory-directed [18 F]FDG PET/CT can alter diagnosis in the majority of the cases, particularly in subjects who were referred because of diagnostic uncertainty. Semi-quantitative assessment may be helpful in establishing a final diagnosis of PMR, supporting the notion that a quantitative whole-body read-out may be useful in unclear cases.

Original languageEnglish (US)
Article number2073
JournalDiagnostics
Volume11
Issue number11
DOIs
StatePublished - Nov 2021
Externally publishedYes

Keywords

  • GCA
  • Giant cell arteritis
  • Inflammation
  • PMR
  • Polymyalgia rheumatica
  • Vasculature
  • Vasculitis
  • [ F]FDG PET/CT

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Whole-body [18 f]fdg pet/ct can alter diagnosis in patients with suspected rheumatic disease'. Together they form a unique fingerprint.

Cite this